Michael Ackermann

This profile gathers the share dealings of Michael Ackermann in Tarsus Pharmaceuticals, Inc., where the filings describe the role as board member. Between 15 June 2021 and 15 June 2022, the trades on record add up to 11 filings.

The open-market side counts 1 purchase for €1.3M alongside 8 sales for €428k. On balance, insiders were net buyers of €852k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 share grant and 1 option exercise. So far in 2022, the count stands at 1 purchase and no sales.

The newest entry dates from 17 June 2022: an option exercise, in Tarsus Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 1,623 days ago, on 9 May 2022. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.